• ResMed's Q1 FY27 GAAP diluted earnings per share rose 23% year over year to $2.92.
• Revenue climbed 6% year over year to $1.41 billion, driven primarily by strong demand for sleep devices, masks and accessories.
• Operating cash flow fell 8% year over year to $422 million, while shareholder returns through repurchases and dividends exceeded $1 billion.
• The MatrixCare divestiture closed, and the AirTouch F40 fabric CPAP mask launched in the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.